Perceived Risk Among Human Immunodeficiency Virus Serodiscordant Couples in East Africa Taking Oral Pre-Exposure Prophylaxis

Sex Transm Dis. 2016 Aug;43(8):471-5. doi: 10.1097/OLQ.0000000000000472.

Abstract

Objectives: Perceived risk of human immunodeficiency virus (HIV) infection is thought to drive low adherence in pre-exposure prophylaxis (PrEP) trials. We explored the level of perceived risk of incident HIV infection in the Partners PrEP Study, in which adherence was generally high.

Methods: A cross-sectional questionnaire assessed perceived risk of HIV at 12 months after enrollment. Logistic regression was used to analyze the relationship between perceived risk and other demographic and behavioral variables.

Results: Three thousand two hundred twenty-six couples from the Partners PrEP Study were included in this analysis. Only 15.4% of participants reported high or moderate perceived risk. Participants at high risk of acquiring HIV were slightly more likely to report high perceived risk (odds ratio, 1.60; 95% confidence interval, 1.30-1.95; P < 0.001); nevertheless, only 20% of participants with high-risk reported high perceived risk.

Conclusions: Participants reported low perceived risk of HIV but were adherent to PrEP. Perceptions of risk are likely socially determined and more complex than Likert scale questionnaires capture.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents / blood*
  • Anti-HIV Agents / therapeutic use
  • Cross-Sectional Studies
  • Female
  • HIV Infections / epidemiology
  • HIV Infections / prevention & control*
  • HIV Seronegativity
  • Heterosexuality
  • Humans
  • Kenya
  • Male
  • Medication Adherence
  • Perception
  • Pre-Exposure Prophylaxis
  • Risk
  • Sexual Partners
  • Surveys and Questionnaires
  • Tenofovir / blood
  • Tenofovir / therapeutic use
  • Uganda
  • Young Adult

Substances

  • Anti-HIV Agents
  • Tenofovir